Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ — Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan…